Sujith R Kalmadi

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage
    Sujith Kalmadi
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44122, USA
    Cancer 107:136-40. 2006
  2. ncbi The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma
    Sujith R Kalmadi
    Cleveland Clinic Foundation, Multiple Myeloma Multidisciplinary Clinical Research Program, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Acta Haematol 116:1-7. 2006
  3. ncbi Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Sujith Kalmadi
    Thoracic and Gastrointestinal oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Med Oncol 23:507-13. 2006
  4. ncbi Lenalidomide: the emerging role of a novel targeted agent in malignancies
    Sujith Kalmadi
    Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Drugs Today (Barc) 43:85-95. 2007
  5. ncbi Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)
    Sujith R Kalmadi
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Lung Cancer 60:259-63. 2008
  6. ncbi Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?
    Khaldoun Almhanna
    Gastrointestinal Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Oncology (Williston Park) 21:1116-22; discussion 1122, 1124, 1127-8. 2007

Detail Information

Publications6

  1. ncbi Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage
    Sujith Kalmadi
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44122, USA
    Cancer 107:136-40. 2006
    ..Epsilon aminocaproic acid (EACA) is an antifibrinolytic drug that has been used to control hemorrhage by stabilizing the thrombus. It has been used in thrombocytopenic patients largely on an empiric basis...
  2. ncbi The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma
    Sujith R Kalmadi
    Cleveland Clinic Foundation, Multiple Myeloma Multidisciplinary Clinical Research Program, Taussig Cancer Center, Cleveland, Ohio 44195, USA
    Acta Haematol 116:1-7. 2006
    ..In this review article we will outline the history, mechanisms of action, pharmacology, and clinical trials of arsenic trioxide in multiple myeloma...
  3. ncbi Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Sujith Kalmadi
    Thoracic and Gastrointestinal oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
    Med Oncol 23:507-13. 2006
    ..This treatment results in almost a doubling of 1-yr survival, along with an improvement in quality of life despite treatment-related toxicities. However, platinum-based treatment may be associated with significant toxicity...
  4. ncbi Lenalidomide: the emerging role of a novel targeted agent in malignancies
    Sujith Kalmadi
    Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Drugs Today (Barc) 43:85-95. 2007
    ..Combination therapy with lenalidomide could enhance this agent's antineoplastic role; this is likely the position it will occupy in the armamentarium against cancer...
  5. ncbi Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810)
    Sujith R Kalmadi
    Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Lung Cancer 60:259-63. 2008
    ..The purpose of this open-label phase II SWOG study was to evaluate the activity of gemcitabine (Gemzar; Eli Lilly, Indiana, USA) and cisplatin combination therapy, in patients with unresectable malignant mesothelioma of the pleura...
  6. ncbi Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?
    Khaldoun Almhanna
    Gastrointestinal Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Oncology (Williston Park) 21:1116-22; discussion 1122, 1124, 1127-8. 2007
    ..This review summarizes the current data on the different modalities used worldwide in the neoadjuvant treatment of hepatocellular carcinoma, the rationale for these approaches, efficacy, potential complications, and future prospects...